Immunization against malaria with a recombinant protein.
We have expressed in bacteria the C-terminal part of Plasmodium yoelii merozoite surface protein-1 (MSP1) containing the two epidermal growth factor-like domains. The protein, either alone or fused to glutathione S-transferase, was highly effective as a vaccine and protected mice against challenge infection. Reduction and alkylation abolished the protection obtained with the protein. This shows for the first time the absolute requirement of the disulphide-bonded conformation for immunogenicity. In a short term experiment, mice were protected against a massive challenge. The immunity was effective at the time of merozoite release/reinvasion. Recombinant protein based on this part of MSP1 may be suitable as a vaccine against malaria.
Ling
I T
IT
Division of Parasitology, National Institute for Medical Research, Mill Hill, London, UK.
Ogun
S A
SA
Holder
A A
AA
D000818:Animals; D001483:Base Sequence; D017931:DNA Primers; D004815:Epidermal Growth Factor / Q000276:immunology; D004926:Escherichia coli / Q000235:genetics; D005982:Glutathione Transferase / Q000276:immunology; D017780:Malaria Vaccines; D020066:Merozoite Surface Protein 1; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000276:immunology; D010967:Plasmodium yoelii / Q000276:immunology*; D011498:Protein Precursors / Q000235:genetics / Q000276:immunology; D015800:Protozoan Proteins / Q000235:genetics / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000276:immunology; D014614:Vaccines, Synthetic
D017931:DNA Primers; D017780:Malaria Vaccines; D020066:Merozoite Surface Protein 1; D010446:Peptide Fragments; D011498:Protein Precursors; D015800:Protozoan Proteins; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic; D004815:Epidermal Growth Factor; D005982:Glutathione Transferase